FindMyKOL
Clinical trialNCT04800367Active, not recruitingPhase 2Interventional

Romosozumab/Denosumab Study for Premenopausal IOP

NCT04800367 is a phase 2 interventional trial sponsored by Columbia University. As of 21 Nov 2026, it is active and no longer recruiting. It studies Denosumab and Romosozumab Prefilled Syringe [Evenity] in Premenopausal Idiopathic Osteoporosis. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 12 Mar 2021 and a primary completion date of 31 Mar 2027.

SponsorColumbia University →Enrollment30Premenopausal Idiopathic Osteoporosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04800367
FieldValue
Registry IDNCT04800367
StatusActive not recruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorColumbia University
Enrollment30
Registered sites1
Countries1
ConditionsPremenopausal Idiopathic Osteoporosis
DrugsDenosumab and Romosozumab Prefilled Syringe [Evenity]
Start12 Mar 2021
Primary completion31 Mar 2027
Study completion31 Mar 2028
Last update posted27 Feb 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overarching goal of the research program is to define optimal treatment for premenopausal women with clinically significant fracture syndromes that require medical therapy. The investigators hypothesize that romosozumab will be associated with improvements in bone mass and microarchitecture in premenopausal women, and also that the responses and response rates will exceed those observed in premenopausal women treated with teriparatide. The investigators will test this hypothesis in this phase 2 study of 30 premenopausal women with idiopathic osteoporosis (IOP) who will receive 12M of romosozumab 210 mg monthly followed by 12M of denosumab 60 mg SC q6M. Aim 1 will define the within-group effects of this regimen. Aim 2 will compare results from participants treated with romosozumab-denosumab to the investigator's well-characterized historical controls treated with teriparatide followed by denosumab.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Columbia University Irving Medical Center

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Denosumab →Romosozumab Prefilled Syringe [Evenity]
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04800367

Each answer restates registry values shown on this page.

What is NCT04800367?

NCT04800367 is a phase 2 interventional trial sponsored by Columbia University. It studies Denosumab and Romosozumab Prefilled Syringe [Evenity] in Premenopausal Idiopathic Osteoporosis.

Is NCT04800367 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04800367?

The registry names Adi Cohen, MD (principal investigator, Columbia University) and Elizabeth Shane, MD (principal investigator, Columbia University) as overall officials.

Where does NCT04800367 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04800367 study?

The registered drug and biological interventions are Denosumab and Romosozumab Prefilled Syringe [Evenity].

When is NCT04800367 expected to complete?

The registry lists a primary completion date of 31 Mar 2027 and a study completion date of 31 Mar 2028. The sponsor last updated the record on 27 Feb 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.